Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was $4.63 for the day, down -0.64% from the previous closing price of $4.66. In other words, the price has decreased by -$0.64 from its previous closing price. On the day, 12.52 million shares were traded. RXRX stock price reached its highest trading level at $4.82 during the session, while it also had its lowest trading level at $4.55.
Ratios:
Our analysis of RXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.58 and its Current Ratio is at 3.58. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.07.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.Needham initiated its Buy rating on March 16, 2023, with a $17 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 26 ’25 when Gibson Christopher sold 100,000 shares for $4.84 per share. The transaction valued at 484,000 led to the insider holds 954,229 shares of the business.
Gibson Christopher bought 100,000 shares of RXRX for $484,000 on Aug 26 ’25. On Aug 18 ’25, another insider, Khan Najat, who serves as the Chief R&D Commercial Officer of the company, sold 36,599 shares for $5.52 each. As a result, the insider received 202,173 and left with 668,197 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2021221888 and an Enterprise Value of 1575456000. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.15 while its Price-to-Book (P/B) ratio in mrq is 2.18. Its current Enterprise Value per Revenue stands at 24.389 whereas that against EBITDA is -2.687.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.90, which has changed by -0.24959481 over the last 52 weeks, in comparison to a change of 0.1716845 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -14.68%, while the 200-Day Moving Average is calculated to be -23.62%.
Shares Statistics:
RXRX traded an average of 27.18M shares per day over the past three months and 15138430 shares per day over the past ten days. A total of 425.48M shares are outstanding, with a floating share count of 332.34M. Insiders hold about 23.45% of the company’s shares, while institutions hold 53.83% stake in the company. Shares short for RXRX as of 1755216000 were 122223405 with a Short Ratio of 4.50, compared to 1752537600 on 115527481. Therefore, it implies a Short% of Shares Outstanding of 122223405 and a Short% of Float of 30.220000000000002.
Earnings Estimates
The current rating of Recursion Pharmaceuticals Inc (RXRX) is the result of assessments by 6.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.26 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.29 and -$1.8 for the fiscal current year, implying an average EPS of -$1.58. EPS for the following year is -$1.28, with 9.0 analysts recommending between -$0.81 and -$1.6.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $23.9M to a low estimate of $16M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $26.08MFor the next quarter, 5 analysts are estimating revenue of $17.7M. There is a high estimate of $20.6M for the next quarter, whereas the lowest estimate is $16M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $95.5M, while the lowest revenue estimate was $48.35M, resulting in an average revenue estimate of $69.68M. In the same quarter a year ago, actual revenue was $58.84MBased on 9 analysts’ estimates, the company’s revenue will be $97.31M in the next fiscal year. The high estimate is $208.4M and the low estimate is $45M.
